Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Guardado en:

Detalles Bibliográficos
Autores principales:	Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7341e3e04ef748e4ab7d4e2752aa2b98
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7341e3e04ef748e4ab7d4e2752aa2b98
record_format	dspace
spelling	oai:doaj.org-article:7341e3e04ef748e4ab7d4e2752aa2b982021-11-12T13:30:05ZSystematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design10.1136/jitc-2021-0031492051-1426https://doaj.org/article/7341e3e04ef748e4ab7d4e2752aa2b982021-09-01T00:00:00Zhttps://jitc.bmj.com/content/9/9/e003149.fullhttps://doaj.org/toc/2051-1426Haiying QinNirali N ShahTerry J FryLila YangJohn A ChukinasSamiksha TarunMarie PouzollesChristopher D ChienLisa M NiswanderAnthony R WelchSarah K TasianNaomi A TaylorBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Haiying Qin Nirali N Shah Terry J Fry Lila Yang John A Chukinas Samiksha Tarun Marie Pouzolles Christopher D Chien Lisa M Niswander Anthony R Welch Sarah K Tasian Naomi A Taylor Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
format	article
author	Haiying Qin Nirali N Shah Terry J Fry Lila Yang John A Chukinas Samiksha Tarun Marie Pouzolles Christopher D Chien Lisa M Niswander Anthony R Welch Sarah K Tasian Naomi A Taylor
author_facet	Haiying Qin Nirali N Shah Terry J Fry Lila Yang John A Chukinas Samiksha Tarun Marie Pouzolles Christopher D Chien Lisa M Niswander Anthony R Welch Sarah K Tasian Naomi A Taylor
author_sort	Haiying Qin
title	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
title_short	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
title_full	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
title_fullStr	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
title_full_unstemmed	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
title_sort	systematic preclinical evaluation of cd33-directed chimeric antigen receptor t cell immunotherapy for acute myeloid leukemia defines optimized construct design
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/7341e3e04ef748e4ab7d4e2752aa2b98
work_keys_str_mv	AT haiyingqin systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT niralinshah systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT terryjfry systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT lilayang systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT johnachukinas systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT samikshatarun systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT mariepouzolles systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT christopherdchien systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT lisamniswander systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT anthonyrwelch systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT sarahktasian systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign AT naomiataylor systematicpreclinicalevaluationofcd33directedchimericantigenreceptortcellimmunotherapyforacutemyeloidleukemiadefinesoptimizedconstructdesign
_version_	1718430442261053440

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Ejemplares similares